ASX | News Release Avita Medical Appoints Adam Kelliher as Chief Executive Officer Australia 14 April 201 5 — Avita Medical Ltd. (ASX: AVH ), (OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, today announced the appointment of Mr. Adam Kelliher as Chief Executive Officer. Tim Rooney, who […]
DUBLIN, Ireland and MELBOURNE, Australia, April 1, 2015 (GLOBE NEWSWIRE) — Link here. Veterinary biologic therapy developer Nexvet Biopharma (Nasdaq:NVET) today announced it has appointed former Division Head of Novartis Animal Health Dr. George Gunn as non-executive chairman of the Nexvet Board of Directors. The appointment is effective from 31 March 2015. Until January 2015, Dr. Gunn […]
SEA: NZX MARKET UPDATE 1 April 2015 SeaDragon Investor Update April 2015 – Link here to attachments. The update includes: • Omega 3 refined fish oil factory takes shape; • The good oil – a word from SeaDragon Chief Executive, Ross Keeley; • Picking the best opportunities; • Omega 3s may alleviate depression; • Sustainability at the […]
RICHMOND, Va. & LJUBLJANA, Slovenia, & SYDNEY — March 31, 2015. Link here. Richmond, VA, USA, Ljubljana, Slovenia, and Sydney, Australia, March 31, 2015 – AmpliPhi BioSciences Corporation. (OTCQB: APHB), the global leader in developing bacteriophage-based antibacterial therapies to treat drug resistant infections, today announced that the European Patent Office (EPO) has granted European patent no. EP […]
Northridge, CA and Cambridge, UK, 11 March 2015 – Link here. Avita Medical Ltd (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today the closing of a placement to sophisticated and institutional investors and launched a Share Purchase Plan (“SPP”). The placement raised $A5,042,280.00 through the issuance […]
March 11, 2015 | By Damian Garde – Link here. AmpliPhi BioSciences has lined up $13 million in private placement cash, selling stock and warrants to fund its pipeline of treatments for drug-resistant bacterial infections. The Richmond, VA, biotech is issuing nearly 79 million shares at $0.165 apiece to a group of investors including partner Intrexon ($XON), […]
March 10, 2015 05:07 PM Eastern Daylight Time. Link here. RICHMOND, Va. & LJUBLJANA, Slovenia & SYDNEY–(BUSINESS WIRE)–AmpliPhi BioSciences Corporation, (OTCQB: APHB), a global leader in bacteriophage-based antibacterial therapies to treat drug resistant infections, announced today that it has entered into definitive purchase agreements of common stock and warrants with a group of institutional accredited investors, […]
Potential breakthrough treatment for chronic pain Part of $10m capital raising BioScience Managers achieved a 24.7% IRR in its previous fund – top decile performance of international private equity and venture capital fund managers. 20 February 2015, Melbourne, Australia: Leading healthcare fund manager BioScience Managers has invested $5 million in novel chronic pain treatment company Saluda […]
Saluda Medical secures $10 million in new financing New funding secured for Saluda Medical is set to open the next chapter in commercialising breakthrough treatment of chronic pain. Link here. Friday, 20 February 2015: Saluda Medical has today announced that it has received $10 million in Series B financing bringing a breakthrough treatment for chronic pain – […]
Northridge, CA and Cambridge, UK, 28 January 2015. Link here. Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY) a regenerative medicine company specializing in the treatment of wounds and skin defects, announced today that the first patient has been enrolled in the Company’s Pivotal Phase III burn trial for ReCell®. The FDA-approved study is designed to confirm the safety and […]